cease and desist tirzepatide Eli Lilly just issued a public warning to the compounding industry. In a recent open letter, the pharmaceutical company raised concerns about products being combined with vitamin B12 marketed in Eli Lilly obesity drug shortage

until it was eventually banned by the FDA in December 2003 due to its risk of cardiovascular adverse effects (AEs).6 This case illustrates the risk associated with the current situation in the U.S., where medications extracted from plants might not be allowed to be marketed as medications

Recent price cuts by manufacturers means Levity represents a considerable markup

For weight loss purposes, many health plans are starting to limit their coverage and a prior authorization will likely need to be approved by the insurer

Once prescribed, patients typically begin at the lowest dose and escalate over weeks per protocol, with regular follow-ups